AdMeTech Co.,Ltd

AdMeTech Co.,Ltd is a medical device manufacturer headquartered in Matsuyama, Ehime Prefecture, Japan. The company was founded in September 2003 as a venture originating from Ehime University, established by researchers from the university's Faculty of Engineering and Faculty of Medicine. Its name is an abbreviation of "Advanced Medical Technology," reflecting its mission of advanced medical-engineering collaboration. AdMeTech specializes in the development of devices and systems that apply high-frequency induction principles to heat a heating element placed in a tumor from outside the body using a high-frequency magnetic field, locally heating the affected area to 60°C or higher to ablate cancer tissue. This technology is intended for minimally invasive cancer treatment. The company has pursued clinical development for cervical intraepithelial neoplasia and other cancers, and has also developed veterinary treatment devices. It obtained various medical device manufacturing and sales licenses in Japan, and its AMTC300B device received medical device approval in Ukraine in 2017, followed by mass production approval in 2018. AdMeTech was listed on the TOKYO PRO Market from September 2013 to July 2019, and continues to operate as a research and development-oriented medical device company.

AdMeTech Co.,Ltd was established on September 4, 2003, as a venture company originating from Ehime University, founded by researchers from the university's Faculty of Engineering and Faculty of Medicine. The company's name stands for "Advanced Medical Technology," signifying its commitment to advanced medical-engineering collaboration. In May 2005, the company established a laboratory within Ehime University. In February 2006, it opened a Tokyo office, and in May 2006 obtained a Class 1 medical device manufacturing and sales license (Tokyo: 13B1X10021). In December 2007, the Tokyo office was relocated to Chiba Prefecture, and the company obtained a Class 1 medical device manufacturing and sales license (Chiba: 12B1X10008). In November 2008, development of a device for treating human cervical intraepithelial neoplasia was completed. In May 2009, the company obtained a Class 1 veterinary medical device manufacturing and sales license (Chiba: 21製販療I第16号), and in September 2009, its veterinary treatment device notification (AMTC200) was accepted by the Ministry of Agriculture, Forestry and Fisheries. In May 2012, clinical trials for high-grade cervical dysplasia began. On September 4, 2013, the company was listed on the TOKYO PRO Market. In October 2013, an investigator-initiated clinical study of immunotherapy combined with hyperthermia for human recurrent advanced cancer was initiated. In April 2015, veterinary clinical trials for lymph node metastatic cancer in animals began at Osaka Prefecture University. In May 2015, joint non-clinical research for inoperable oral cancer started at Tsurumi University. In June 2015, a basic patent for local heating technology was established. In September 2015, the company obtained licenses for highly controlled medical device sales and leasing, as well as veterinary highly controlled medical device sales and leasing. In March 2017, the company acquired ISO9001 certification, and its AMTC300B received medical device approval in Ukraine. In November 2017, it obtained a manufacturing license. In July 2018, AMTC300B received mass production approval for medical devices in Ukraine. On July 1, 2019, the company was delisted from the TOKYO PRO Market. In December 2019, it obtained ISO13485 certification. As of 2024, the company was selected as a subsidy recipient under the Tokyo Metropolitan Advanced Medical Device Acceleration Project.

• Company founded.

• New laboratory established within Ehime University.

• Tokyo office established.

• Obtained Class 1 medical device manufacturing and sales license (Tokyo).

• Tokyo office relocated to Chiba Prefecture; obtained Class 1 medical device manufacturing and sales license (Chiba).

• Completed development of device for human cervical intraepithelial neoplasia treatment.

• Obtained Class 1 veterinary medical device manufacturing and sales license.

• Veterinary treatment device notification (AMTC200) accepted by MAFF.

• Clinical trials for high-grade cervical dysplasia started.

• Listed on TOKYO PRO Market.

• Investigator-initiated clinical study of immunotherapy combined with hyperthermia for recurrent advanced cancer started.

• Veterinary clinical trials for lymph node metastatic cancer started at Osaka Prefecture University.

• Joint non-clinical research for inoperable oral cancer started at Tsurumi University.

• Basic patent for local heating technology established.

• Obtained highly controlled medical device sales and leasing licenses (human and veterinary).

• Acquired ISO9001 certification; AMTC300B received medical device approval in Ukraine.

• Obtained manufacturing license.

• AMTC300B received mass production approval in Ukraine.

• Delisted from TOKYO PRO Market.

• Acquired ISO13485 certification.

• Selected as a subsidy recipient for the Tokyo Metropolitan Advanced Medical Device Acceleration Project.

R&D-oriented medical device venture developing minimally invasive cancer treatment technology.

• AMTC300B

  High-frequency induction hyperthermia system for cancer treatment; received medical device approval in Ukraine in 2017 and mass production approval in 2018.

• AMTC200

  Veterinary treatment device; notification accepted by MAFF in 2009.

1. 1アドメテック - 熱による新しい「がん治療」の研究と医療機器の開発 (愛媛県松山市)admetech.co.jp
2. 2アドメテック - Wikipediaja.wikipedia.org
3. 3AdMeTech Co.,Ltd - Wikidatawikidata.org